Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ingrid Oosterhuis"'
Publikováno v:
Drug Safety, 46(1), 65-75. ADIS INT LTD
Introduction: Due to the COVID-19 vaccination campaign, national pharmacovigilance (PV) centres had to deal with high volumes of Individual Case Safety Reports (ICSRs) that needed to be processed and assessed in a short time span. This necessitated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12cb4bad5a0c4820e56fb41b699b09dd
https://research.rug.nl/en/publications/fbff546c-285b-4295-9d5c-33d67ea10591
https://research.rug.nl/en/publications/fbff546c-285b-4295-9d5c-33d67ea10591
Publikováno v:
Expert Opinion on Drug Safety, 17(2), 111-115. Taylor & Francis Ltd
Background: To make a proper causality assessment of an adverse drug reaction (ADR) report, a certain level of clinical information is necessary. A tool was developed to measure the level of clinical information present in ADR reports. The aim of thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4500ed14090c8e36e179f4ddcc17ca5f
https://doi.org/10.1080/14740338.2018.1400008
https://doi.org/10.1080/14740338.2018.1400008
Autor:
H. Taavola, Victoria Newbould, Ola Caster, Petar Mas, Philip Michael Tregunno, Ingrid Oosterhuis, Sara Gama, Linda Härmark
Publikováno v:
Drug Safety
Introduction Spontaneous reporting of suspected adverse drug reactions is key for efficient post-marketing safety surveillance. To increase usability and accessibility of reporting tools, the Web-Recognising Adverse Drug Reactions (WEB-RADR) consorti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46dc1e2a3383a86c70eb0d30b796af04
https://pubmed.ncbi.nlm.nih.gov/29761281
https://pubmed.ncbi.nlm.nih.gov/29761281
Publikováno v:
Drug Safety. 30:919-990
Background In August 2006, the Netherlands Pharmacovigilance Centre Lareb started with Lareb Intensive Monitoring (LIM). The main objective of LIM is to monitor the safety of new drugs. Patients eligible for participation are identified using the fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54ca434d222c7853e057b6394adff432
https://doi.org/10.2165/00002018-200730100-00112
https://doi.org/10.2165/00002018-200730100-00112
Publikováno v:
Drug Safety, 37(6), 449-457. ADIS INT LTD
BACKGROUND: Although a concise overview of adverse drug reactions (ADRs) to varenicline is available, little is known about the use of varenicline in daily practice and time-related information about ADRs.OBJECTIVE: The aim of this study was to gain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2edcf6970cea4633c612203083b8b17f
https://pubmed.ncbi.nlm.nih.gov/24817484
https://pubmed.ncbi.nlm.nih.gov/24817484
Publikováno v:
European Journal of Clinical Pharmacology, 68(10), 1461-1462. Springer Verlag
The Netherlands Pharmacovigilance Centre Lareb maintainsthe spontaneous adverse drug reaction (ADR) reportingsystem in the Netherlands. The primary aim of this systemis to detect ADRs that were not identified prior to drugmarketing [1]. Physicians, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be012c75d4942a5a2ea2e91e3293c7f0
https://research.rug.nl/en/publications/edb503f1-772d-4771-866a-b6f665419ce6
https://research.rug.nl/en/publications/edb503f1-772d-4771-866a-b6f665419ce6
Publikováno v:
Drug Safety, 35(3), 221-232. ADIS INT LTD
Background: In 2010, the Netherlands Pharmacovigilance Centre Lareb received more than 4000 reports from healthcare professionals (HCPs). All HCPs received individual personal feedback containing information about the reported drug-adverse drug react
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88f34bbc7f2738554bbc5f2ed5c43ecd
https://pubmed.ncbi.nlm.nih.gov/22201474
https://pubmed.ncbi.nlm.nih.gov/22201474